Get the Stockscreener App
1.08
12.20%
-0.15
Allogene Therapeutics Inc stock is traded at $1.08, with a volume of 19.09M.
It is down -12.20% in the last 24 hours and down -8.47% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.23
Open:
$1.225
24h Volume:
19.09M
Relative Volume:
5.17
Market Cap:
$236.23M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5094
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-28.00%
1M Performance:
-8.47%
6M Performance:
-40.00%
1Y Performance:
-60.58%
1-Day Range:
$1.00
$1.225
1-Week Range:
$1.00
$1.5299
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.08 | 269.04M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics Faces Market Volatility Amid Financial Challenges - StocksToTrade
Allogene Resets Clinical Course After Patient Death In Lymphoma Study - Benzinga
Regeneron cancer bispecific rejected again; Allogene discloses trial death - BioPharma Dive
When is Allogene Therapeutics Inc. stock expected to show significant growthLow Risk Alerts With Proven Results - jammulinksnews.com
Allogene Therapeutics updates ALPHA3 trial protocol following safety event - Investing.com
Allogene Therapeutics Adjusts ALPHA3 Trial After Adverse Event - TipRanks
RENT Form 144: Insider plans to sell 262 shares worth $1.49k | ALLO SEC FilingForm 8-K - Stock Titan
Allogene Therapeutics Announces Selection of Standard FC Lymphodepletion Regimen in ALPHA3 Study Following Consultation with FDA and Safety Board - Quiver Quantitative
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma - The Manila Times
How volatile is Allogene Therapeutics Inc. stock compared to the marketAI Powered Tracker With Low Risk - jammulinksnews.com
Allogene says lymphodepletion drug caused patient death, changes CAR-T study design - Endpoints News
Allogene Therapeutics shares rise 2.33% premarket after Robbins LLP class action filing. - AInvest
How does Allogene Therapeutics Inc. compare to its industry peersBest Dividend Updates From AI Tools - jammulinksnews.com
Understanding Allogene Therapeutics Inc.’s price movementCommunity Entry Consensus Trade Ideas Shared - metal.it
Allogene Therapeutics Inc. Trading Near Value Zone — Recovery AheadWatchlist for Low Risk High Return Stocks Updated - metal.it
RSI Crosses Above 30 for Allogene Therapeutics Inc. — Reversal in SightLow Volatility Stable Growth Picks Rank High - metal.it
Published on: 2025-07-29 12:47:04 - metal.it
What are the technical indicators suggesting about Allogene Therapeutics Inc.Earnings Report Outlook For 2025 - jammulinksnews.com
CAR-T Cell Therapy Market is projected to grow to US$ 20.4 billion - openPR.com
Allogene Therapeutics Inc. Forms Bullish Flag — Upside AheadLow Drawdown Real Time Trading Tips Shared - metal.it
What is the risk reward ratio of investing in Allogene Therapeutics Inc. stockBest Dividend Forecasts To Watch Now - jammulinksnews.com
Does Allogene Therapeutics Inc. stock perform well during market downturnsPre Market Ideas For Beginners - jammulinksnews.com
How does Allogene Therapeutics Inc. generate profit in a changing economyAchieve breakthrough financial results today - jammulinksnews.com
What are Allogene Therapeutics Inc. company’s key revenue driversTrack top-performing stocks effortlessly - jammulinksnews.com
What are the latest earnings results for Allogene Therapeutics Inc.Build wealth faster with consistent investment plans - jammulinksnews.com
What institutional investors are buying Allogene Therapeutics Inc. stockBuild a diversified portfolio for steady growth - jammulinksnews.com
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update - ADVFN Brasil
Allogene’s ALLO-329: A New Frontier in Autoimmune Disease Treatment - TipRanks
Is Allogene Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - PrintWeekIndia
What drives Allogene Therapeutics Inc. stock priceHigh-velocity gains - PrintWeekIndia
Global Allogeneic Cell Therapy Market to grow at 25% CAGR on rising demand and trials by 2030 - PharmiWeb.com
Is Allogene Therapeutics Inc. stock a good hedge against inflationConsistent triple returns - jammulinksnews.com
Allogene Therapeutics Inc. Stock Analysis and ForecastExplosive trading growth - PrintWeekIndia
Multiple Insiders Sold Allogene Therapeutics Shares Presenting Weak Signs For Investors - 富途牛牛
What analysts say about Allogene Therapeutics Inc. stockRapid return acceleration - Autocar Professional
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Allogene Therapeutics shares rise 8.00% intraday after CytoMed Therapeutics successfully completed dose level 1 of its Phase I clinical trial. - AInvest
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 - Yahoo Finance
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):